期刊文献+

钠-葡萄糖协同转运蛋白2抑制剂对糖尿病肾病治疗作用的研究进展 被引量:19

Research progress of Sodium-glucose cotransporter 2 inhibitors on treatment of diabetic nephropathy
下载PDF
导出
摘要 糖尿病肾病是糖尿病最常见的微血管并发症之一,是导致终末期肾病的主要原因之一。糖尿病肾病发病机制复杂,治疗难度大,近年来钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂成为了治疗糖尿病肾病的研究热点,其可有效降低血糖,还可改善肾高滤过状态、改善肾缺氧、降低蛋白尿、减轻体重、降低血压、降低血尿酸、减轻炎症和氧化应激等。文章就SGLT-2抑制剂降糖特点、SGLT-2抑制剂对肾保护作用、SGLT-2抑制剂不良反应等三方面的研究进展作一综述。 Diabetic nephropathy(DN)is one of the most common microvascular complications of Diabetes mellitu.It is one of the leading causes of End-stage renal diseae(ESRD).The pathogenesis of DN is complex and difficult to treat.In recent years,Sodium-glucose cotransport 2(SGLT-2)inhibitors have become a research hotspot in the treatment of DN.They could effectively lower blood glucose,improve renal hyperfiltration and hypoxia,reduce urinary protein,weight,blood pressure and uric acid.In addition,SGLT2 is also anti-inflammatory and antioxidative,etc.This article reviews the progress of SGLT-2 inhibitors in 3 aspects,including the hypoglycemic characteristics,the protective effects of SGLT-2 inhibitors on the kidney,as well as the adverse reactions of SGLT-2 inhibitors.
作者 尹一帆(综述) 刘建(审校) YIN Yi-fan;LIU Jian(Department of Nephrology,The Affiliated Hospital of Southwest Medical University,Nephropathy Clinical Medical Research Center of Sichuan Province,Luzhou 646000,Sichuan,China;Department of Nephrology,The Affiliated Chinese Traditional Medicine Hospital of Southwest Medical University,Luzhou 646000,Sichuan,China)
出处 《医学研究生学报》 CAS 北大核心 2020年第1期97-102,共6页 Journal of Medical Postgraduates
基金 四川省科学技术厅-泸州市人民政府-泸州医学院联合科研专项资金(LY-448)
关键词 钠-葡萄糖协同转运蛋白2 糖尿病肾病 肾保护 不良反应 sodium-glucose co-transport 2 inhibitors diabetic nephropathy kidney protection adverse effects
  • 相关文献

参考文献4

二级参考文献30

  • 1王谦,肖争流,胡斌,李长贵.醛糖还原酶基因多态性与糖尿病肾病的相关性研究[J].医学研究生学报,2005,18(4):346-348. 被引量:2
  • 2Rocco MV, Bleyer A J, Burkart JM. Utilization of inpatient and outpatient resources for management of hemodialysis access complications[J]. Am J Kidney Dis, 1996, 28(2) : 250-256.
  • 3Taber TE, Maikranz PS, Haag BW, et al. Maintenance of adequate hemodialysis access [ J ]. ASAIO J, 1995, 41 (4) :842-846.
  • 4Redfem AB, Zimmerman NB. Neurologic and ischemic complications of upper extremity vascular access for dialysis [ J ]. J Hand Surg, 1995, 20(2) :199-204.
  • 5Uldall R, Besley ME, Thomas A, et al. Maintaining the patency of double-luman silatic jugular catheters for haemodialysis [ J ].Int J Artif Organs,1993, 16( 1 ) : 37-40.
  • 6Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival in diabetic patients on hemodialysis[J]. Diabetes Care, 2001, 24(5) : 909-913.
  • 7Ponikvar R, Ponikvar JB. Management of diabetic patients with haemodialysis, peritoneal dialysis, and renal transplantation [ J ].Nephrol Dial Transplant, 2001, 16( Suppl 6) : 94-96.
  • 8McMurray S, Johnson G, Davis S, et al. Diabetes education and care management significantly improve patient outcomes in the dialysis unit[J]. Am J Kidney Dis, 2002, 40(3) : 566-575.
  • 9Blowey DL, Balfe JW, Gupta I, et al. Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension[J]. Am J Kidney Dis, 1996, 28( 1 ) : 132-136.
  • 10Charra B, VoVan C, Marcelli D, et al. Diabetes mellitus in tassin, fance: remarkable transformation in incidence and outcome of ESRD in diabetes[ J]. Adv Renal Replacement Ther, 2001,8( 1 ) : 42-56.

共引文献100

同被引文献157

引证文献19

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部